These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 15075747)

  • 1. Cardiac allograft vasculopathy: advances in understanding its pathophysiology, prevention, and treatment.
    Pinney SP; Mancini D
    Curr Opin Cardiol; 2004 Mar; 19(2):170-6. PubMed ID: 15075747
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients.
    Eisen HJ; Tuzcu EM; Dorent R; Kobashigawa J; Mancini D; Valantine-von Kaeppler HA; Starling RC; Sørensen K; Hummel M; Lind JM; Abeywickrama KH; Bernhardt P;
    N Engl J Med; 2003 Aug; 349(9):847-58. PubMed ID: 12944570
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of Everolimus Initiation and Calcineurin Inhibitor Elimination on Cardiac Allograft Vasculopathy in De Novo Heart Transplant Recipients.
    Arora S; Andreassen AK; Karason K; Gustafsson F; Eiskjær H; Bøtker HE; Rådegran G; Gude E; Ioanes D; Solbu D; Dellgren G; Ueland T; Aukrust P; Gullestad L;
    Circ Heart Fail; 2018 Sep; 11(9):e004050. PubMed ID: 30354362
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cardiac allograft vasculopathy: current concepts.
    Ventura HO; Mehra MR; Smart FW; Stapleton DD
    Am Heart J; 1995 Apr; 129(4):791-9. PubMed ID: 7900633
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cardiac allograft vasculopathy.
    Rhodes LR
    Crit Care Nurs Q; 2004; 27(1):10-6. PubMed ID: 14974521
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cardiac allograft vasculopathy by intravascular ultrasound in heart transplant patients: substudy from the Everolimus versus mycophenolate mofetil randomized, multicenter trial.
    Kobashigawa JA; Pauly DF; Starling RC; Eisen H; Ross H; Wang SS; Cantin B; Hill JA; Lopez P; Dong G; Nicholls SJ;
    JACC Heart Fail; 2013 Oct; 1(5):389-99. PubMed ID: 24621971
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Heterogeneity of cardiac allograft vasculopathy: clinical insights from coronary angioscopy.
    Mehra MR; Ventura HO; Jain SP; Ramireddy K; Ali A; Stapleton DD; Smart FW; Ramee SR; Collins TJ; White CJ
    J Am Coll Cardiol; 1997 May; 29(6):1339-44. PubMed ID: 9137233
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differential effect of everolimus on progression of early and late cardiac allograft vasculopathy in current clinical practice.
    Masetti M; Potena L; Nardozza M; Prestinenzi P; Taglieri N; Saia F; Pece V; Magnani G; Fallani F; Coccolo F; Russo A; Rapezzi C; Grigioni F; Branzi A
    Am J Transplant; 2013 May; 13(5):1217-26. PubMed ID: 23621161
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cardiac allograft vasculopathy compared by intravascular ultrasound sonography: everolimus to mycophenolate mofetil--one single-center experience.
    Chou NK; Jan CF; Chi NH; Lee CM; Wu IH; Huang SC; Chen YS; Yu HY; Tsao CI; Ko WJ; Chu SH; Wang SS
    Transplant Proc; 2012 May; 44(4):897-9. PubMed ID: 22564578
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evolving concepts and treatment strategies for cardiac allograft vasculopathy.
    Benatti RD; Taylor DO
    Curr Treat Options Cardiovasc Med; 2014 Jan; 16(1):278. PubMed ID: 24346852
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of allograft vasculopathy in heart transplantation.
    Segovia J; Gómez-Bueno M; Alonso-Pulpón L
    Expert Opin Pharmacother; 2006 Dec; 7(17):2369-83. PubMed ID: 17109612
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevention of cardiac allograft vasculopathy with Certican (everolimus): the Stanford University experience within the Certican Phase III clinical trial.
    Valantine H
    J Heart Lung Transplant; 2005 Apr; 24(4 Suppl):S191-5; discussion S210-1. PubMed ID: 15774321
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pathogenetic mechanisms of cardiac allograft vasculopathy--impact of nitric oxide.
    Koglin J
    Z Kardiol; 2000; 89 Suppl 9():IX/24-7. PubMed ID: 11151787
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predictive model to assess risk for cardiac allograft vasculopathy: an intravascular ultrasound study.
    Mehra MR; Ventura HO; Chambers R; Collins TJ; Ramee SR; Kates MA; Smart FW; Stapleton DD
    J Am Coll Cardiol; 1995 Nov; 26(6):1537-44. PubMed ID: 7594082
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of everolimus introduction on cardiac allograft vasculopathy--results of a randomized, multicenter trial.
    Arora S; Ueland T; Wennerblom B; Sigurdadottir V; Eiskjær H; Bøtker HE; Ekmehag B; Jansson K; Mortensen SA; Saunamaki K; Simonsen S; Gude E; Bendz B; Solbu D; Aukrust P; Gullestad L
    Transplantation; 2011 Jul; 92(2):235-43. PubMed ID: 21677600
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cardiac allograft vasculopathy.
    Lee MS; Finch W; Weisz G; Kirtane AJ
    Rev Cardiovasc Med; 2011; 12(3):143-52. PubMed ID: 22080925
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sirolimus as primary immunosuppression attenuates allograft vasculopathy with improved late survival and decreased cardiac events after cardiac transplantation.
    Topilsky Y; Hasin T; Raichlin E; Boilson BA; Schirger JA; Pereira NL; Edwards BS; Clavell AL; Rodeheffer RJ; Frantz RP; Maltais S; Park SJ; Daly RC; Lerman A; Kushwaha SS
    Circulation; 2012 Feb; 125(5):708-20. PubMed ID: 22207715
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tissue characterization of progressive cardiac allograft vasculopathy in patients with everolimus therapy compared with donor-transmitted atherosclerosis assessed using serial intravascular imaging: a case report.
    Watanabe T; Kotani J; Murata Y; Seguchi O; Yanase M; Nakatani T
    Transplant Proc; 2014 Sep; 46(7):2456-61. PubMed ID: 25242801
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cardiac allograft vasculopathy: current concepts.
    Ventura HO; Smart FW; Stapleton DD; Toups T; Price HL
    J La State Med Soc; 1993 May; 145(5):195-8, 200-2. PubMed ID: 8393471
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term efficacy of everolimus as de novo immunosuppressant on the cardiac allograft vasculopathy in heart transplant recipients.
    Choi HI; Kang DY; Kim MS; Lee SE; Ahn JM; Lee JY; Kim YH; Park DW; Jung SH; Kim JJ
    Atherosclerosis; 2022 Sep; 357():1-8. PubMed ID: 35981436
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.